Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
  • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
  • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
  • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
  • C07D451/06—Oxygen atoms
  • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• the present invention relates generally to a novel process for the preparation of anticholinergic agents/drugs, such as umeclidinium bromide (I) (chemical name: 4- [hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide), tiotropium bromide (II) (chemical name: 1a ⁇ )-7-[(hydroxy-di-2- thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azonia-tricyclo[3.3.1.0 2 ' 4 ]nonane bromide), glycopyrronium bromide (III) (chemical name: 3-(2-cyclopentyl-2-hydroxy-2- phenylacetoxy)-1 ,1-dimethylpyrrolidinium bromide), aclidinium bromide (IV) (chemical name:3(R)-(2-hydroxy-2,2-dithien-2
• the compounds of molecular structures (l-V) depicted above are known-anticholinergic drugs with different applications, mainly used for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
• COPD chronic obstructive pulmonary disease
• Umeclidinium bromide is a highly effective active pharmaceutical ingredient used for preparing pharmaceutical compositions to be administered as a dry powder for oral inhalation at once-daily micrograms dose. New compositions, combinations, forms of administration (e.g. metered-dose inhalers) and dosages using umeclidinium bromide are being developed.
• WO 2005/104745 relates to a process for the preparation of umeclidinium bromide, wherein the reaction is carried out in chlorinated solvents for a time period of between 16 hours and 24 hours:
• umeclidinium bromide Unsolvated crystalline polymorphic forms of umeclidinium bromide have been disclosed (WO 2014/027045, US 9273001 B2) as the active pharmaceutical ingredient showing that the compound may give rise to a variety of crystalline solid state form having distinct physical properties.
• the preparation of pure umeclidinium bromide in a single, pure crystalline form with a consistent level of crystallinity and chemical purity has been a challenge to the industry due to the compound’s high susceptibility to form solvates.
• Umeclidinium bromide solvates namely methanol solvate (CZ27764 (Sanofi)), ethanol, 2-propanol, 2-methylpropan-1-ol, chlorobenzene and p-xylene solvates (WO 2014/027045, US 9657011 B2) have been identified.
• umeclidinium bromide 1 -propanol has been used as solvent to minimize the solvate formation (WO 2014/027045, US 965701 1 B2) avoiding the resuspension of the compound in ethyl acetate, methanol and water, which was previously required (example 84, Method B, WO 2005/104745).
• EP3248970 relates to solid forms of umeclidinium bromide, in particular to its non- solvated form 1 , crystalline forms A and B and an amorphous form.
• Form A is prepared by crystallization from a solution of umeclidinium bromide in a mixture of methanol and water in the volume ratio of 1 : 1 to 2:1.
• Form B is obtained from form A at a temperature higher than 180°C.
• WO 2018/087561 relates to a process for the preparation of umeclidinium bromide having high purity, wherein the reaction is carried out for a time period of between 18 h to 24 h, the solvent is selected from cyclic ethers such as tetrahydrofuran, aromatic solvents, such as toluene, ketones such as acetone and protic solvents such as water or combinations thereof, to form a product with a single, pure crystalline form with a consistent level of crystallinity and chemical purity.
• the solvent is selected from cyclic ethers such as tetrahydrofuran, aromatic solvents, such as toluene, ketones such as acetone and protic solvents such as water or combinations thereof, to form a product with a single, pure crystalline form with a consistent level of crystallinity and chemical purity.
• Tiotropium bromide is a highly effective active pharmaceutical ingredient which is administrated in low (microgram) therapeutic doses by inhalation. Crystalline polymorphic forms of tiotropium bromide have been reported in various publications, including US6777423, EP14101445, EP16825442, EP1879888, EP2085396,
• EP1869035 and WO201 1/01588, showing that the compound may give rise to a variety of solid forms having distinct physical properties.
• EP2814827 describes a process where tiotropium bromide is obtained by crystallization in a mixture comprising methanol and acetone, in a single pure anhydrous crystalline form.
• RU2453547 provides a crystalline hemi-n-propanol solvate of tiotropium bromide, designated as Form 12, prepared by crystallization from a solution of tiotropium bromide in n-propanol.
• Form 12 a crystalline hemi-n-propanol solvate of tiotropium bromide, designated as Form 12, prepared by crystallization from a solution of tiotropium bromide in n-propanol.
• US8865903 relates to a continuous flow process for the preparation of quaternary ammonium salts, such as tiotropium bromide (II), glycopyrronium bromide (III) or ipratropium bromide (V) with high yield and purity in polar aprotic solvents selected from the group consisting of amides, nitriles and sulphoxides such as acetonitrile, dimethylformamide, dimethylacetamide, N-methylpyrrolidone and dimethylsulfoxide.
• polar aprotic solvents selected from the group consisting of amides, nitriles and sulphoxides such as acetonitrile, dimethylformamide, dimethylacetamide, N-methylpyrrolidone and dimethylsulfoxide.
• the invention describes that dichloromethane is a poor solvent for the final product, which may precipitate in the continuous-flow reactor and obstruct the channels.
• US8865903 teaches
• the present inventors have recognized there exists a need for a more efficient process for preparing anticholinergic drugs.
• a process that offers advantages over the known processes for the preparation of anticholinergic agents The inventors have now devised such a process.
• the advantages of the present invention include, but are not limited to, a very efficient process with reduced reaction time, improved operability, temperature control, yield and a reduced cost of the final product, which is critical to optimize any synthetic process. Notably, even a small improvement in reaction design can lead to significant savings in a large scale production.
• the present invention discloses a continuous flow process for the preparation of anticholinergic drugs, such as umeclidinium bromide, tiotropium bromide, glycopyrronium bromide, aclidinium bromide or ipratropium bromide, in one or more polar protic solvents, preferably 1 -propanol, water or a mixture of 1 -propanol and water to form a single, pure crystalline form with good yield and excellent chemical purity.
• anticholinergic drugs such as umeclidinium bromide, tiotropium bromide, glycopyrronium bromide, aclidinium bromide or ipratropium bromide
• a process for the preparation of an anticholinergic agent wherein the process is carried out in continuous flow mode using one or more polar protic solvents.
• a process for the preparation of one or more anticholinergic drugs such as umeclidinium bromide, tiotropium bromide, glycopyrronium bromide, aclidinium bromide or ipratropium bromide in one or more polar protic solvents such as 1 -propanol, water or a mixture of 1 -propanol and water, in continuous flow mode.
• anticholinergic drugs such as umeclidinium bromide, tiotropium bromide, glycopyrronium bromide, aclidinium bromide or ipratropium bromide in one or more polar protic solvents such as 1 -propanol, water or a mixture of 1 -propanol and water, in continuous flow mode.
• the inventors of the present invention have found that the reaction time of the process disclosed in the present invention is extremely reduced from 16-24 hours to 1-20 minutes.
• the anticholinergic agent obtained using the novel process described in the present invention may be a single, pure solid crystalline form with a consistent level of crystallinity and chemical purity.
• the anticholinergic agents obtained from the process of the present invention can be formulated, preferably with at least one pharmaceutically acceptable excipient, wherein the composition is suitable for inhalation.
• the pharmaceutical composition comprises the anticholinergic agent obtained by the process of the present invention and one or more additional active pharmaceutical ingredients.
• the pharmaceutical composition may be in the form of a dry powder, a solution or a suspension.
• the present invention provides a process for the preparation of an anticholinergic drug, in continuous flow mode in the presence of one or more polar protic solvents.
• the anticholinergic drug disclosed in the present invention includes, but not limited to, umeclidinium bromide, tiotropium bromide, glycopyrronium bromide, aclidinium bromide and ipratropium bromide.
• a process for the preparation of umeclidinium bromide comprising reacting 1-azabicyclo[2.2.2]oct-4- yl(diphenyl)methanol (VI) with ((2-bromoethoxy)methyl)benzene (VII) in one or more polar protic solvents in continuous flow mode.
• Any polar protic solvent that do not form a solvate with the anticholinergic drug disclosed in the present application may be used in the process of the present invention.
• the one or more polar protic solvents used in the process disclosed in the present invention includes, but not limited to, 1 -propanol, water, a mixture of 1 -propanol and water, or any isomer of propanol or butanol, such as n-propanol, n-butanol.
• the ratio of 1 -propanol and water in the mixture of 1 -propanol and water is in the range of from about 30:1 to 1 :1.2, preferably about 25: 1.
• a skilled person can determine the amount of starting material or chemicals, such as cyclic tertiary amines, alkylating agents, to be used in the process of preparing an anticholinergic drug disclosed in the present invention.
• the concentration of 1-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (VI) to be used is dependent on the solubility of the compound at a specific temperature at which the reaction is carried out.
• a concentration in the range of from about 1 to about 10 mol/L equivalent of ((2-bromoethoxy)methyl)benzene (VII) may be used in the process.
• the novel process of the present invention requires no further resuspension or recrystallization of the drug to obtain an unsolvate form.
• the process for the preparation of the anticholinergic agent/drug disclosed in the present invention may comprise using one or more flow procedures to carry out the continuous flow mode process.
• flow procedures as used herein relates to those procedures, for example, the use of certain apparatus and/or certain conditions, necessary to enable the continuous running of chemical synthesis.
• Flow procedures does not encompass a traditional batch process.
• a continuous reactor is used to carry material as a flowing stream, as will be understood by those skilled in this field.
• a process may be defined as continuous in that it is characterized by continuous feeding of the reactants to the reactor with continuous formation and exiting of a product stream.
• a continuous process disclosed in the present invention may be advantageous for a number of reasons including, but not limited to, improved purity and yield of the product and reduced effluent; thus, making the present process more environmentally friendly.
• continuous flow reactor is used to refer to those reactors which enable chemical reactions to occur in a continuous flow.
• Continuous flow reactors may also be known as continuous tubular reactors.
• the continuous flow reactor may comprise a pipe reactor, a plug flow reactor, a tube reactor or another commercially available continuous flow reactor, or a combination of two or more such reactors.
• the starting materials or chemicals such as cyclic tertiary amines, alkylating agents, is preferably in the form of a solution dissolved in a suitable solvent, such as the polar protic solvents disclosed in the present invention and fed continuously into a continuous-flow reactor.
• a solution comprising 1-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (VI) and ((2- bromoethoxy)methyl)benzene (VII) is prepared, preferably in a polar protic solvent such as 1 -propanol, water or in a mixture of 1 -propanol and water.
• a polar protic solvent such as 1 -propanol, water or in a mixture of 1 -propanol and water.
• the solution of 1- azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (VI) and ((2-bromoethoxy)methyl)benzene (VII) is introduced into a continuous flow reactor separately or, as an alternative, the solutions comprising the reactants can be pre-mixed before the introduction into the continuous flow reactor.
• the temperature under which the reaction in the polar protic solvent, such as 1 -propanol, water or a mixture of 1 -propanol and water is carried out, is preferably in the range of from about 120 °C to about 200 °C.
• the reaction temperature is above 140 °C.
• the reaction temperature is in the range of from about 140 °C to about 180 °C.
• the reaction temperature is in the range of above 140 °C to 180 °C. More preferably, the reaction temperature is in the range of from about 141 °C to about 180 °C. Most preferably, the reaction temperature is in the range of from about 150 °C to 180 °C.
• the reaction time of the process disclosed in the present invention is extremely reduced from 16-24 hours to 1-20 minutes. Consequently, the reaction time of the process of the present invention is preferably in the range of from about 1 to about 20 minutes, preferably the reaction time of the process of the present invention is in the range of from about 2 to about 20 minutes, more preferably the reaction time of the process of the present invention is in the range of from about 5 to about 20 minutes, most preferably the reaction time of the process of the present invention in the range of from about 5 to about 10 minutes.
• the flow rate may be adjusted in order to obtain an optimal residence time of the reaction mixture in the continuous flow reactor with the aim of completing the reaction.
• the flow rate of reaction mixture through the one or more continuous flow reactors may be controlled, altered or adjusted depending on the chemical reaction to be carried out, and the reactor model being used.
• Flow and pressure ranges used are characteristics of the reaction model. A skilled person can determine the flow rate and pressure ranges depending upon the reactor model being used. For example, in the case of a custom-made stainless steel coil reactor, typically the flow is in the range of from about 0.11 to about 0.84 mL/min and the pressure is in the range of from about 3 to 34 about bar.
• the product is isolated by removing the solvent from the reaction mixture.
• the reaction mixture obtained from the reactor may be concentrated under reduced pressure.
• An anti-solvent preferably water may be added to the concentrated product to form an aqueous suspension.
• the aqueous suspension may be cooled down to a temperature, preferably in the range of from about 0 °C to about 5 °C or from above 0 °C to about 5 °C, and thereafter the solid crystalline form of the product is isolated, preferably by filtration.
• the filtered product may be washed and/or dried, preferably under reduced pressure to obtain the product in yields up to 80%.
• the purity of the product obtained by following the procedure described in the present invention is in a single crystalline form typically 398.5% by HPLC.
• the product obtained is preferably umeclidinium bromide.
• XRPD X-Ray Powder Diffraction
• DSC Differential Scanning Calorimetry
• TGA Thermogravimetric Analysis
• the process disclosed in the present invention is useful for the preparation of umeclidinium bromide.
• the anticholinergic agents such as umeclidinium bromide, tiotropium bromide, glycopyrronium bromide, aclidinium bromide or ipratropium bromide obtained by the process disclosed in the present invention may be further micronized to obtain material with adequate particle size which is suitable for inhalation.
• the present invention also provides an anticholinergic drug, such as, umeclidinium bromide, tiotropium bromide, glycopyrronium bromide, aclidinium bromide or ipratropium bromide obtained by the novel process of the present invention.
• the anticholinergic drug is umeclidinium bromide.
• the anticholinergic drugs are in a form suitable for inhalation.
• the crystalline form of the anticholinergic drugs obtained by the process of the present invention may be in an unsolvated form.
• the present invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising an anticholinergic drug disclosed herein, preferably umeclidinium bromide obtained by the process of the present invention and at least one pharmaceutically acceptable excipient.
• the pharmaceutical composition is suitable for inhalation, preferably in the form of a dry powder, a solution or a suspension.
• the pharmaceutical composition of the present invention may further comprise an additional one or more active pharmaceutical ingredients.
• the one or more active pharmaceutical ingredients .used in the pharmaceutical composition disclosed in the present invention includes, but not limited to, Vilanterol trifenatate, Fluticasone furoate or a combination therof.
• compositions may be prepared by admixing an anticholinergic drug disclosed herein, preferably umeclidinium bromide obtained by the novel process of the present invention and one or more pharmaceutically acceptable excipients.
• the pharmaceutical composition of the present invention is for use as a medicament, preferably for use in treating respiratory diseases such as asthma or chronic obstructive pulmonary disease (COPD).
• COPD chronic obstructive pulmonary disease
• the present invention further provides a method for the treatment in a mammal, such as a human, for treating respiratory, inflammatory or obstructive airway disease such as COPD and asthma, which method comprises administration of a therapeutically effective amount of a pharmaceutical composition of the present invention.
• the dosage and mode of administration can be decided by the expert of the art, based on the common general knowledge.
• compositions may be formulated to be delivered by any suitable route, including oral, intravenous, parenteral, inhalation, intranasal, topical, subcutaneous, or intramuscular.
• compositions of the present invention may be administered by any suitable method used for delivery of drugs to the respiratory tract.
• the composition of the present invention may thus be administered using metered dose inhalers (MDI), dry powder inhalers (DPI), nebulisers, nasal sprays, nasal drops, insufflation powders, sprays and spray patches.
• MDI metered dose inhalers
• DPI dry powder inhalers
• nebulisers nasal sprays, nasal drops, insufflation powders, sprays and spray patches.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Emergency Medicine (AREA)
• Otolaryngology (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=71120199

Family Applications (1)

Country Status (10)

Citations (13)

Family Cites Families (1)

• 2019
  • 2019-06-17 PT PT115583A patent/PT115583B/pt active IP Right Grant
• 2020
  • 2020-06-16 AU AU2020296972A patent/AU2020296972B2/en active Active
  • 2020-06-16 WO PCT/GB2020/051448 patent/WO2020254791A1/en not_active Ceased
  • 2020-06-16 KR KR1020227000471A patent/KR20220024433A/ko active Pending
  • 2020-06-16 JP JP2021574905A patent/JP2022549545A/ja active Pending
  • 2020-06-16 US US17/617,725 patent/US20220251078A1/en active Pending
  • 2020-06-16 CA CA3141271A patent/CA3141271A1/en active Pending
  • 2020-06-16 CN CN202080049646.2A patent/CN114206863A/zh active Pending
  • 2020-06-16 EP EP20734291.6A patent/EP3982923B1/en active Active
• 2021
  • 2021-12-13 IL IL288972A patent/IL288972A/en unknown
• 2025
  • 2025-02-20 JP JP2025025794A patent/JP2025081547A/ja active Pending

Patent Citations (15)

Also Published As

Similar Documents

Legal Events